CALR ligand 1 (Compound 2a) is a calreticulin (CALR) ligand. CALR ligand 1 shows antitumor activity against triple-negative breast cancer (TNBC) cells (IC50=0.1 μM). CALR ligand 1 induces intracellular calcium overloading and triggers apoptosis in TNBC cells. CALR ligand 1 is promising for research of TNBC .

AZ'320 is an ATP-competitive necroptosis (EC50 of 4.9 μM) inhibitor and a RIPK1 (pKD of 5.45) inhibitor. AZ'320 inhibits necroptosis by inhibiting RIPK1 phosphorylation. AZ’320 prevents mortality of the mice and rescues temperature and body weight in SIRS mice models. AZ'320 can be used for researches of cancer and inflammation.

ER-67880 is a potent microtubule inhibitor. ER-67880 exhibits anti-proliferative activity against KB, Colon 38 and P338 cells with IC50s of 0.55, 0.2 and 0.76 μg/mL. ER-67880 causes G2/M phase arrest and is accompanied by abnormal DNA replication. ER-67880 exhibits a down-regulation pattern of G1 phase-related genes, suggesting potential dehydrogenase inhibitory activity. ER-67880 can be used in various cancer studies, including those of nasopharyngeal carcinoma and murine adenocarcinoma.

L742791 is a β3-AR agonist. L742791 elicits lipolytic response in isolated nonhuman primate adipocytes.

PF-04363467 is a highly preferring D3R antagonist. PF-04363467 produces dose-dependent changes in the EEG profile of freely moving rats. PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects. PF-04363467 can be used for the study of addiction, cognitive and mental illness.

SRT6, an anticancer agent is a CD44 inhibitor. SRT6 inhibits key CD44-associated kinases, including SRC, ERBB2 and MAPKAPK2. SRT6 has strong tumor selectivity over non-tumoral lung cells and significant antiproliferative activity against cancer cells (EC50of 1.37  μM for NCI-H23 cells).

BVT-74316 is a 5-HT6 receptor antagonist. BVT-74316 can reduce food intake and bodyweight gain in rodent models. BVT-74316 can be used for the research of metabolic disease, such as obesity.

GG-818 is a potent and selective α1 adrenoceptor antagonist, with pKi values of 9.7 for α1a, 7.8 for α1b, and 7.6 for α1d. GG-818 can be used for benign prostatic hyperplasia research.

IIIM-1266 is a NLRP3 inflammasome inhibitor. IIIM-1266 inhibits IL-1β release in mouse macrophages (J774A.1 cells) (IC50 = 2.3 μM) and significantly reduced the protein expression level of mature IL-1β. IIIM-1266 can be used for the study of inflammation.

Potassium perfluorohexanesulfonate is an orally active surfactant found in sera of the general population. Potassium perfluorohexanesulfonate induces adaptive hepatocellular hypertrophy, decreases serum cholesterol and increases alkaline phosphatase in male mice.

Perfluoroheptanesulfonic acid (1-Perfluoroheptanesulfonic acid; Perfluoroheptanesulphonic acid) is a perfluoroalkyl substance (PFAS). PFHpS can induce malformations in zebrafish larvae (EC50=168.1 μM). It has also been found in landfill leachate, and fetal exposure to PFHpS can lead to reduced birth weight.

LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes.

CS 461 is a cephalosporin antibiotic. CS 461 shows potent and well-balanced antibacterial activity against Gram-positive and Gram-negative bacteria including some β-lactamase producing species. CS 461 can be used for the research of infection.

Isodimethoate is a thermal decomposition product of Dimethoate. Isodimethoate is a direct anticholinesterase agent and shows an inhibition to human red blood cell acetylcholinesterase (AChE).

8-Br-GTP (tetrasodium) (8-Bromoguanosine-5'-triphosphate (tetrasodium)) is a derivative of the energy substrate – GTP, for protein synthesis and gluconeogenesis. 8-Br-GTP (tetrasodium) inhibits the E. coli GTPase FtsZ with a Ki of 31.8 μM. 8-Br-GTP (tetrasodium) promotes the assembly of porcine brain microtubules.

isoGTP (Isoguanosine-5'-O-triphosphate) sodium is an isomer of guanosine 5'-triphosphate and a phosphorylated form of Crotonoside. isoGTP sodium inhibits transcription and induces T to C mutations in a reverse transcriptase assay. isoGTP sodium is promising for research of substrate specificity of phosphofructokinase and mutT homolog 1 (MTH1).

3′-Azido-2′,3′-dideoxy-CTP (AZddCTP) is a cytidine analog containing a 3-azido group. As a chain terminator, 3′-Azido-2′,3′-dideoxy-CTP can be incorporated into the nascent DNA chain by HIV reverse transcriptase. 3′-Azido-2′,3′-dideoxy-CTP terminates DNA synthesis due to the lack of a 3'-hydroxyl group, thereby inhibiting viral replication. 3′-Azido-2′,3′-dideoxy-CTP has IC50 values of 15.6 μM and 160.8 μM for WT HIV and AZTR HIV. 3′-Azido-2′,3′-dideoxy-CTP has antiviral activity.

3′-Azido-2′,3′-dideoxy-GTP (AZddGTP) is a selective telomerase inhibitor with a Ki value of 1.5 μM. 3′-Azido-2′,3′-dideoxy-GTP can be incorporated into the 3′-terminus of DNA by telomerase. 3′-Azido-2′,3′-dideoxy-GTP inhibits telomerase activity in HeLa cells in vitro.

isoGDP (trisodium) is a GDP isomer. isoGDP (trisodium) is a phosphorylated form of crotonoside. isoGDP (trisodium) is an inhibitor of mitochondrial ATPase with an IC50 of 3 μM.

(S)-STO021 is a highly selective, orally effective ERβ agonist. (S)-STO021 has a dual activity of inhibiting osteoclast activity and promoting osteoblast activity. (S)-STO021 can be used for research on osteoporosis.

8-ET-NAD+ (sodium) is the derivative of NAD+. 8-ET-NAD+ (sodium) can be used in screening of PARP1 gatekeeper mutations. 8-ET-NAD+ (sodium) can be studied in research on cancer.

Ganciclovir triphosphate (GCV-TP) disodium is a synthetic 2'-deoxyguanosine analog with activity in inhibiting human cytomegalovirus (CMV) replication. Ganciclovir triphosphate disodium is effective against CMV infection by binding to viral DNA polymerase and interfering with viral DNA synthesis. Ganciclovir triphosphate disodium has an IC50 of 0.01 μM against CMV strains from humans, monkeys, mice, and guinea pigs. Ganciclovir triphosphate disodium has also been used in gene-directed enzyme prodrug inhibition for cancer inhibition.

BMS-663749 is an HIV attachment inhibitor and phosphonooxymethyl prodrug of BMS-488043.

Scyllo-Inositol hexakisphosphate (Scyllo-IP6) sodium is a orthophosphate monoester found in lake sediments.

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS. It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate.

U-031 is an anti-tumor agent. U-031 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. U-031 is commonly used in cancer research.

Squalamine (phosphate) (Compound ENT-01) is an orally active neuroprotective agent. Squalamine (phosphate) can displace α-Syn that is bound electrostatically to nerve cell membranes and prevent aggregation of α-Syn. Squalamine (phosphate) can be used for the research of neurological disease, such as Parkinson’s disease.

CGS 26303 is an endothelin-converting enzyme (ECE) inhibitor. CGS 26303 increases the expression of endothelin-converting enzyme-1 in endothelial cells. CGS 26303 attenuates cerebral vasospasm in a rabbit subarachnoid hemorrhage model. CGS 26303 improves birth survival and alleviates pulmonary hypoplasia in newborn rats in a rat model of congenital diaphragmatic hernia. CGS 26303 can be used for research on cardiovascular and cerebrovascular diseases and congenital diaphragmatic hernia.

K-757 is a GPR40 agonist with an EC50 of 2.1 ± 0.2 nM for human GPR40. K-757 exhibits a half-life of 1-11 h in Preclinical Species. K-757 stimulates GLP-1 secretion and has potential applications in bariatric research.

CGP-6809 is an orally active DNA inhibitor. CGP-6809 exhibits antitumor activity against various transplantable tumors in mice and rats, including melanoma, prostate cancer, and rectal cancer. CGP-6809 can be used in research on various cancers, including melanoma, prostate cancer, and rectal cancer.